In this episode, Stacie Lindsey talks about the importance in understanding the recent FDA clearance of Praxis's Investigational New Drug (IND) - PRAX-222 EMBRAVE - that used patient data from Invitae Ciitizen in its clinical trial. This opens the doors for advancing research using data from patient registries, like ICPR.
cholangiocarcinoma.org